Skip to main content
OpenTrials
Completed

NCT Number: NCT04798053

Impact of COVID-19 Pandemic and Social Distancing on Mental Health of Chronic Inflammatory Rheumatism Affected Patients

Recent studies have highlighted the consequences of COVID-19 pandemic and social distancing on mental health of individuals. The aim of this study is to evaluate those consequences within a sample of inflammatory chronic rheumatism affected patients, taking into account the well-known key role of stress in the set-up of such diseases.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The previous H1N1 and SRAS-1 pandemics, that required to containment and quarantine, have lead to the emergence of mental symptoms such as stress, anxiety, insomnia… The French COCONEL study during the COVID pandemic have shown the major psychological impact of this crisis on the population, leading to stress and fears.

Stressful life events are well-known factors of chronic inflammatory rheumatisms set-up or flare. The aim of this study is therefore to evaluate the psychological impact of COVID-19 pandemic on chronic inflammatory rheumatism (CIR) affected patients.

A case-control prospective multicentric study will be performed on 212 CIR patients versus 106 controls to compare the stress level in each group. Patient reported outcomes will be evaluated, using electronic questionnaires, as well as classical clinical informations on CIR evolution during a 6-months follow-up period. An ancillary study on 100 patients will also be realized to quantify cytokine serum levels and determinate transcriptomic profiles.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

For the cases:

Inclusion criteria

  • adult patient (age over 18 years old)
  • patient affected by a chronic inflammatory rheumatism (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Systemic lupus, Still disease, scleroderma…)
  • patient without any language difficulty
  • affiliated to an health insurance system
  • and who agree to participate in the study

For controls :

Inclusion criteria

  • adult patient (age over 18 years ol
  • patient affected by a non-inflammatory or degenerative musculo-skeletal disease during the containment period,
  • patient without any language difficulty,
  • affiliated to an health insurance system,
  • and who agree to participate in the study.

For cases and controls :

Exclusion criteria

  • pregnant or lactating patient
  • psychiatric patient
  • patient under guardianship or other legal protection regimen.

Treatment and study plan

Questionnaire

Behavioral

14-item Perceived Stress Scale (PSS-14), 9-item Patient Health Questionnaire (PHQ-9 questionnaire), State Trait Inventory Anxiety questionnaire (STAI questionnaire), Post-traumatic Stress Disorder Checklist Scale (PCL-S questionnaire)

blood sample and salivary sample

Biological

10 ml whole blood for Peripheral blood and 2 ml saliva sample. Only for 100 cases.

Primary outcomes

  1. Change from Baseline stress level according to 10-item Perceived Stress Scale (PSS-10) at 3 months and 6 months after inclusion

    Time frame: At inclusion (day 0), 3 months and 6 months after inclusion

    that varies between 10 and 50 with higher values mean greater difficulties to deal with stress

Secondary outcomes

  1. Proportion of patients affected by depression according to 9-item Patient Health Questionnaire (PHQ-9)

    Time frame: At inclusion (day 0), 3 months and 6 months after inclusion

    that varies between 0 and 27 with higher values mean greater severity of depression

  2. Proportion of patients affected by anxiety symptoms according to State-Trait Anxiety Inventory questionnaire

    Time frame: At inclusion (day 0), 3 months and 6 months after inclusion

    that varies between 20 and 80 with higher values mean higher levels of anxiety

  3. Proportion of patients affected by post-traumatic stress disorder symptoms according to Post-traumatic stress disorder Check-List Scale (PCL-S) questionnaire

    Time frame: At inclusion (day 0), 3 months and 6 months after inclusion

    that varies between 17 and 85 with higher values mean greater intensity of stress disorder

  4. Evaluation of tobacco consumption evolution compared to the pre-COVID19 pandemic (less, same or more)

    Time frame: At inclusion (day 0), 3 months and 6 months after inclusion

  5. Evaluation of alcohol consumption evolution compared to the pre-COVID19 pandemic (less, same or more)

    Time frame: At inclusion (day 0), 3 months and 6 months after inclusion

  6. Evaluation of drugs consumption evolution compared to the pre-COVID19 pandemic (less, same or more)

    Time frame: At inclusion (day 0), 3 months and 6 months after inclusion

  7. Evaluation of CIR treatments compliance continuation compared to the pre-COVID19 pandemic (without any modification, intensification, diminution, discontinuation).

    Time frame: At inclusion (day 0), 3 months and 6 months after inclusion

  8. Evaluation of chronic inflammatory rheumatism activity scores using Visual Analog Scale (VAS)

    Time frame: At inclusion (day 0), 3 months and 6 months after inclusion

    that varies between 0 and 100mm with higher value mean higher value means higher level of disease activity.

  9. Evaluation of the impact of COVID-19 diagnostic on the stress level according to 10-item Perceived Stress Scale (PSS-10)

    Time frame: At inclusion (day 0), 3 months and 6 months after inclusion

    that varies between 10 and 50 with higher values mean greater difficulties to deal with stress

  10. Evaluation of the impact of COVID-19 diagnostic on CIR activity using Visual Analog Scale (VAS)

    Time frame: At inclusion (day 0), 3 months and 6 months after inclusion

    that varies between 0 and 100mm with higher value mean higher value means higher level of disease activity

  11. Levels of pro-inflammatory cytokines in sera of CIR patients

    Time frame: At inclusion (day 0) and 6 months after inclusion

    TNF-alpha, IL1, IL6, IL10, IL12, IL17, TGF-beta), expressed in UI per milliliter.

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Collaborators

  • Societe Francaise de Rhumatologie

Registry information

Acronym: EMOPTION

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Mar 15, 2021
Registry last updated
Jun 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.